- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00424827
A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
A Phase II Trial of Cetuximab, Gemcitabine, 5-Fluorouracil and Radiation Therapy in Locally Advanced Non-metastatic Pancreatic Adenocarcinoma
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
During cycle I (chemoradiation), gemcitabine (200 mg/m2) and cetuximab 400mg/m2 initial dose followed by 250mg/m2 IV weekly will be given with continuous infusion 5-FU (200 mg/m2/day) delivered 5 of every 7 days and concurrent external beam radiation therapy. Cetuximab, gemcitabine and 5-FU will begin on the first week of external beam radiotherapy and will continue throughout the course of external beam radiation therapy, and will be discontinued following the conclusion of external beam radiation therapy. All patients will have a central venous access device placed to facilitate chemotherapy administration.
During cycles 2 through 5 (chemotherapy), gemcitabine will be administered at a dose of 1000 mg/m2 over 30 minutes followed by cetuximab at a dose of 250mg/m2 over 30 minutes weekly for 3 weeks followed by one-week rest for four cycles.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histological confirmation of pancreatic adenocarcinoma is required.
- Only patients with unresectable, non-metastatic tumors are eligible.
- Documentation of disease extent by endoscopic ultrasound and either laparotomy or laparoscopy must be performed within 42 days of registration.
- All patients will also be assessed by chest x-ray and abdominal-pelvic CT scan.
- Confirmation of palliative surgical bypass at the time of laparotomy or whether a biliary stent was placed will be requested.
Disease must be locoregional and not amenable to surgery based on one or more of the following criteria:
- size of pancreatic tumor > 5 cm.
- lymph nodes (bulky, > 2 cm, but within a radiation port)
- vascular involvement or impingement of major vessels (superior mesenteric artery, superior mesenteric vein, portal vein, hepatic artery).
- invasion into the adjacent structures.
- Patients with either measurable or evaluable disease are eligible.
- Patients with evidence of peritoneal seeding by malignancy are not eligible for the study.
- Patients with other evidence of metastatic disease are not eligible.
- Patients with concurrent malignancy of any site, except limited basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, are ineligible.
- Patients with any other malignancy within 5 years of study entry, except curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, are ineligible.
- Patients may not have had prior therapy for carcinoma of the pancreas, nor prior abdominal radiation therapy.
- Age > 18 years.
- CTC performance status < 2.
- No myocardial infarction in the past six months.
- No major surgery in the past two weeks.
- No uncontrolled serious medical or psychiatric illness.
Required Initial Laboratory Data:
- Total bilirubin < 2.0 mg/dl
- AST < 3x upper limits of normal.
- Serum creatinine < 2.0 mg/dl
- WBC > 3,000/mm3 (ANC>1500/mm3)
- Platelets > 100,000 mm3
- CA 19-9
Required Diagnostic procedures:
- Chest X-ray
- Abdominal pelvic CT scan
- EUS
- Staging laparoscopy or staging laparotomy
Exclusion Criteria:
Enrollment in this trial will be limited to patients for whom protocol therapy is safe and appropriate. Physicians should consider the risks and benefits of therapy together with all relevant medical and other considerations in deciding whether this protocol is appropriate for a particular patient. Specific considerations include:
- Psychiatric illness which would prevent the patient from giving informed consent.
- Serious medical illness such as uncontrolled infection, severe cardiovascular disease including recent (< 6 months) myocardial infarction or uncontrolled congestive heart failure, or other serious illness which would limit anticipated survival to < 12 weeks.
- Protocol treatment would pose significant risk to an unborn child. Pregnant women should not be enrolled, and women of child-bearing age should be strongly encouraged to practice effective birth control during and for three months after the trial.
- Inability to swallow medication. Patients should have adequate, unassisted oral intake.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Gemcitabine/Fluorouracil with External Beam Radiation
This protocol will assess the antitumor activity of Gemcitabine/Fluorouracil with External Beam Radiation in patients with non-metastatic, locally advanced pancreatic carcinoma.
|
This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy.
Prazo: 1-year
|
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
|
1-year
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Sobrevivência geral
Prazo: Até 2 anos
|
Até 2 anos
|
|
Biomarker Response to Chemoradiation Therapy
Prazo: 1-year
|
20% decrease in biomarker (CA19-9) from baseline
|
1-year
|
Resection Rate
Prazo: 1-Year
|
1-Year
|
|
Toxicity Associated With This Regimen.
Prazo: 1-Year
|
1-Year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Venu Bathini, MD, University of Massachusetts, Worcester
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Neoplasias
- Neoplasias por local
- Doenças do Sistema Endócrino
- Neoplasias do Aparelho Digestivo
- Neoplasias das Glândulas Endócrinas
- Doenças pancreáticas
- Neoplasias Pancreáticas
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Antivirais
- Inibidores Enzimáticos
- Antimetabólitos, Antineoplásicos
- Antimetabólitos
- Agentes Antineoplásicos
- Agentes imunossupressores
- Fatores imunológicos
- Agentes Antineoplásicos Imunológicos
- Gemcitabina
- Fluorouracil
- Cetuximabe
Outros números de identificação do estudo
- UM200602
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de pâncreas
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos